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OBJECTIVE: To assess the relationship between low maternal serum 25-hydroxyvitamin D levels and gestational
diabetes mellitus in Turkish pregnant women according to the severity of 25-hydroxyvitamin D deficiency and
assess intact parathyroid hormone levels in women with gestational diabetes mellitus and controls with low
and sufficient 25-hydroxyvitamin D levels.
METHODS:We analyzed serum 25-hydroxyvitamin D and intact parathyroid hormone levels in 234 women with
gestational diabetes mellitus and 168 controls. To define the deficiency status, 25-hydroxyvitamin D levels were
further classified into severely deficient, deficient, insufficient and sufficient groups.
RESULTS: Women with gestational diabetes mellitus had significantly lower 25-hydroxyvitamin D levels
compared to controls (30.8¡16.3 vs. 36.0¡16.2 nmol/L). However, when subgroups of 25-hydroxyvitamin D
were analyzed, gestational diabetes mellitus was significantly more common only in women with severely
deficient 25-hydroxyvitamin D levels. After adjusting for covariates, only severely deficient 25-hydroxyvitamin D
levels were independently associated with an increased relative risk of gestational diabetes mellitus. The
relative risk of gestational diabetes mellitus in women with insufficient and deficient 25-hydroxyvitamin D
levels was not statistically significant. Intact parathyroid hormone concentrations were also significantly higher
in women with gestational diabetes mellitus compared to the controls (45.3¡26.2 vs. 38.7¡27.6 pg/ml).
CONCLUSIONS: The results obtained from this study provide novel data indicating that only severely deficient
maternal serum 25-hydroxyvitamin D levels are significantly associated with an elevated relative risk of
gestational diabetes mellitus, even after adjusting for established risk factors of gestational diabetes mellitus.
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& INTRODUCTION
25-hydroxyvitamin D (25OHD) is well known for its
function in maintaining calcium and phosphorus home-
ostasis. In addition to its classical actions, a growing body of
evidence has linked 25OHD deficiency with an increased
risk of cardiovascular disease, some infectious, malignant
and autoimmune diseases and diabetes mellitus (DM) (1,2).
25OHD deficiency is common during pregnancy. Bodnar
et al. demonstrated that 29.2% of Black and 5% of White
pregnant women residing in a northern United States city
had 25OHD deficiency (3). The results of publications
investigating the relationship between low maternal serum
25OHD levels and gestational diabetes mellitus (GDM) are
controversial (4-7). Some of these publications suggested a
relationship between 25OHD deficiency and GDM, while
others failed to find such a relationship, despite an
association between low 25OHD levels and insulin resis-
tance during pregnancy (4-7). Although the results of all of
these studies are interesting, none of these studies have
addressed the relationship between low maternal serum
25OHD levels and GDM according to the severity of 25OHD
deficiency.
Vitamin D and parathyroid hormone (PTH) are both
responsible for maintaining extracellular calcium (Ca)
homeostasis (8). Vitamin D contributes to intestinal Ca
absorption, while low serum Ca levels stimulate PTH
secretion from the parathyroid gland to increase the renal
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reabsorption of Ca and the resorption of Ca from bone (8).
This condition is known as secondary hyperparathyroidism
and has been suggested to increase the risk of DM (9-11).
However, previous studies investigating the relationship
between low maternal serum 25OHD levels and GDM were
limited by their inability to account for PTH levels.
Therefore, this study was designed to assess the relationship
between low maternal serum 25OHD levels and GDM
according to the severity of 25OHD deficiency and assess
PTH levels in women with GDM and controls with low and
sufficient 25OHD levels in a large number of Turkish
pregnant women with GDM and controls.
& MATERIALS AND METHODS
This cross-sectional study was conducted at the diabetes
out-patient clinic of the Sisli Etfal Training and Research
Hospital. Four hundred and two consecutive pregnant
women referred to our center for an oral glucose tolerance
test (OGTT) between January 2010 and April 2011 were
included in the study. All of the study participants were
residing in Istanbul (41 0˚0’N). According to the month of
admission for OGTT, all of the participants were divided
into spring-summer (May-October) and autumn-winter
(November-April) groups. Pregnant women with pre-
gestational diabetes, chronic disease or a history of
consumption of drugs that interact with 25OHDmetabolism
and pregnant women with strict religious clothing were not
included in the study. The study was designed in
accordance with the Helsinki Declaration of 1975, informed
consent was obtained from all participants, and the study
was approved by the local ethics committee.
A 75 g OGTT was performed in all participants at 24-28
weeks’ gestation. Plasma glucose levels (PGLs) were
assessed immediately during OGTT using the glucose
oxidase method. GDM was defined if at least one of the
following diagnostic criteria was met: fasting, 1-hour or 2-
hour PG levels $5.1 mmol/L, 10 mmol/L or 8.5 mmol/L,
respectively (12).
Venous blood samples (20 mL) were also collected from
each participant into plain (no additive) glass tubes on the
day that the OGTT was performed (at 24-28 weeks’
gestation) for the assessment of 25OHD and intact PTH
(iPTH). Maternal serum 25OHD levels were measured using
an electrochemiluminescence method (Roche Diagnostics
GmBH, Mannheim, Germany), with inter-assay and intra-
assay coefficients of variation (CVs) of 2.4 and 5.7%,
respectively. To define the deficiency status, maternal serum
levels of 25OHD were further classified into four groups:
,12.5 nmol/L, severely deficient; 12.5-24.9 nmol/L, defi-
cient; 25-49.9 nmol/L, insufficient; and $50 nmol/L, suffi-
cient. Maternal serum iPTH levels were measured
immediately after blood collection using a chemilumines-
cence immunoassay method (Roche Cobas, Roche
Diagnostics GmBH, Mannheim, Germany), with a mean
inter-assay CV of 6%. The experimental design of the study
is presented in Figure 1.
Data regarding pre-pregnancy body mass index (BMI),
parity, history of type 2 DM in first-degree relatives and the
presence of GDM in previous pregnancies were obtained
through one-on-one meetings with each participant and
from antenatal visit records. BMI was calculated as the
weight in kilograms divided by the height in meters
squared.
& STATISTICAL ANALYSIS
Data were analyzed using SPSS version 15.0.0 for
Windows (SPSS Inc., Chicago, IL). Two-sided tests were
used throughout. Categorical data were evaluated using a
chi-square analysis or Pearson’s correlation and Fisher’s
exact tests as appropriate. Student’s t test and the Mann-
Whitney U test were used to compare parametric quantita-
tive and non-parametric data, respectively. Analysis of
variance (ANOVA) was used to compare quantitative
variables within groups, followed by post-hoc analyses for
multiple comparisons. A logistic regression analysis was
used to estimate the odds ratios (ORs) and 95% confidence
intervals (95% CIs). GDM was included as a dependent
variable in the model. Covariates included in the model as
independent variables included maternal serum 25OHD,
age, previous history of GDM, history of type 2 DM in first-
degree relatives and pre-pregnancy BMI. Scale variables
were presented as the mean¡ standard deviation (mean¡
SD). A p-value ,0.05 was considered to be statistically
significant.
& RESULTS
The participants’ characteristics and baseline biochemical
features are summarized in Table 1. Women with GDM
had a higher pre-pregnancy BMI, had higher parity, were
more likely to have a history of GDM in previous
pregnancies and a history of type 2 DM in first-degree
relatives, and were older compared with controls. In the
current study, 64 (15.9%) pregnant women were classified
as severely 25OHD deficient, 79 (19.7%) as deficient, 196
(48.8%) as insufficient and 63 (15.7%) as sufficient. Of the
study participants, 230 (57%) were admitted during the
autumn-winter months and 172 (43%) during the spring-
summer months. The maternal serum 25OHD levels were
28¡16.3 and 39¡14.4 nmol/L during the autumn-winter
and spring-summer months, respectively (p,0.001). As
expected, severe 25OHD deficiency and 25OHD deficiency
were significantly more common during the autumn-
winter months than the spring-summer months (p,0.0001
for both comparisons).
In this study, women with GDM had significantly lower
25OHD levels compared to controls (Table 1). However,
when subgroups of 25OHD were analyzed, GDM was
significantly more common only in pregnant women with
severely deficient 25OHD levels compared to those with
deficient, insufficient or sufficient 25OHD levels (p,0.0001
for all comparisons). Nevertheless, the frequency of GDM
was not significantly different when pregnant women with
deficient 25OHD levels were compared with those with
insufficient and sufficient 25OHD levels (p=0.89 and
p= 0.14, respectively) or when pregnant women with
insufficient 25OHD levels were compared with those with
sufficient 25OHD levels (p= 0.10). After adjusting for
maternal age, previous history of GDM, history of type 2
DM in first-degree relatives and pre-pregnancy BMI, low
maternal serum 25OHD levels were not associated with an
increased relative risk of GDM when 25OHD was intro-
duced as a single independent variable into the logistic
regression analysis (OR=1.01, 95% CI 1.003–1.03, p=0.14).
When subgroups of 25OHD were separately introduced into
the model, the OR of GDM in women with insufficient and
deficient 25OHD levels was also not statistically significant
(OR= 1.46, 95% CI 1.27–2.74, p= 0.23, OR= 1.64, 95% CI
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1.26–3.43, p= 0.18, respectively). However, after adjusting
for all these factors, pregnant women classified as being
severely deficient for 25OHD had a 3.9-fold increased
relative risk of GDM compared to those with sufficient,
insufficient and deficient 25OHD levels (OR= 3.95, 95% CI
1.68–9.25, p=0.002).
Likewise, as presented in Table 2, the fasting PGL was
significantly higher in pregnant women with severely
deficient 25OHD levels compared to those with deficient,
insufficient and sufficient 25OHD levels (p,0.0001 for all
comparisons). An inverse correlation was also found
between the fasting PGL and 25OHD levels (r =20.18,
p,0.0001). In addition, the inverse relationship between
25OHD and fasting PGL became more significant when the
25OHD level of women with severely deficient 25OHD
levels was correlated with fasting PGL (r =20.28, p= 0.024).
However, no relationship was found between 2-hour PGL
and 25OHD levels (r =20.08, p= 0.10). An inverse correla-
tion was also found between pre-pregnancy BMI and
25OHD levels (r =20.157, p=0.002). Similar to GDM,
Figure 1 - Study experimental design. DM: diabetes mellitus, GDM: gestational diabetes mellitus, OGTT: oral glucose tolerance test, PGL: plasma glucose,
25OHD: 25-hydroxyvitamin D, iPTH: intact parathyroid hormone.
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pre-pregnancy BMI was also significantly higher in preg-
nant women with severely deficient 25OHD levels com-
pared to those with deficient, insufficient and sufficient
25OHD levels (Table 2). The inverse correlation between
25OHD and fasting PGL and BMI in the study participants
is presented in Figures 2 A and B.
iPTH levels above the normal laboratory reference ranges
(secondary hyperparathyroidism) were present in 26
(40.6%) of 64 pregnant women with severely deficient
levels, 26 (32.9%) of 79 pregnant women with deficient
levels, 6 (3%) of 196 pregnant women with insufficient levels
and none of those with sufficient 25OHD levels. As
expected, an inverse association was also found between
iPTH and 25OHD levels (r =20.42, p,0.0001). However, no
association was found between iPTH concentrations and
fasting or 2-hour PGL (r = 0.037, p=0.45, r =20.01, p= 0.83,
respectively). The inverse correlation between 25OHD and
iPTH concentrations is presented in Figure 2 C, and the
differences in fasting PGL, 2-hour PGL, pre-pregnancy BMI
and iPTH concentrations between pregnant women with
severely deficient levels and those with deficient, insuffi-
cient and sufficient 25OHD levels are summarized in
Table 2.
& DISCUSSION
As shown in Table 1, only 28 (12%) of 234 women with
GDM and 35 (20.8%) of 168 controls had sufficient 25OHD
levels, indicating a high prevalence of hypovitaminosis D
during pregnancy. Moreover, 51% of women with GDM
and 56% of those with normal glucose tolerance were taking
a multivitamin supplement that contained 500 IU cholecal-
ciferol. Considering the adverse effects of maternal vitamin
D deficiency on offspring, such as neonatal hypocalcemia,
seizure, impaired development and rickets (13,14), the high
prevalence of hypovitaminosis D during pregnancy is a
major public health problem, and vitamin D supplementa-
tion during pregnancy is of paramount importance.
In the current study, 25OHD levels were significantly
lower in pregnant women with GDM compared to controls.
However, when subgroups of 25OHD concentrations were
analyzed, the difference between 25OHD levels in women
with GDM and controls was only significant in pregnant
women with severely deficient 25OHD levels, and only
severely deficient maternal serum 25OHD levels were
associated with an increased risk of GDM after controlling
for established risk factors of GDM, including maternal age,
Table 1 - Clinical and baseline biochemical characteristics of the study participants.
Women with GDM (n=234) Controls (n = 168) p-value
Maternal age (years) 31.6¡6.0* 29.8¡5.2* 0.002
Pre-pregnancy BMI (kg/m2) 26.7¡5.37* 24.2¡3.79* ,0.0001
Parity
Multiparous 201 (85.9%) 102 (60.7%) ,0.0001
Primigravida 33 (14.1%) 66 (39.3%) ,0.0001
Previous history of GDM 46 (19.7%) 4 (2.4%) ,0.0001
Family history of type 2 DM 89 (38.0%) 28 (16.7%) ,0.0001
Gestational age{ at OGTT 26.4¡1.5* 26.2¡1.5* NS
Fasting PGL (mmol/L) 5.53¡0.75* 4.67¡0.31* ,0.0001
2-hour PGL (mmol/L) 10.3¡1.7* 7.05¡1.0* ,0.0001
25OHD (nmol/L) 30.8¡16.3* 36.0¡16.2* 0.002
Severely deficient (,12.5) 51 (21.8%) 13 (7.7%) ,0.0001
Deficient (12.5-24.9) 45 (19.2%) 34 (20.2%) NS
Insufficient (25-49.9) 110 (47.0%) 86 (51.2%) NS
Sufficient ($50) 28 (12.0%) 35 (20.8%) NS
iPTH (pg/ml) 45.3¡26.2* 38.7¡27.6* 0.016
25OHD: 25-hydroxyvitamin D,*: mean ¡ standard deviation.
{: weeks, BMI: body mass index, DM: diabetes mellitus, GDM: gestational diabetes mellitus, NS: non-significant, OGTT: oral glucose tolerance test, PGL:
plasma glucose.
Table 2 - Differences in fasting and 2-hour PGL levels, pre-pregnancy BMI and iPTH concentrations between pregnant women with











Severely 5.69¡0.76 ,0.0001 9.50¡1.97 NS 27.97¡5.01 0.001 60.21¡29.91 NS
Deficient
Deficient 5.04¡0.61 8.73¡2.24 24.88¡4.38 58.27¡40.92
Severely 5.69¡0.76 ,0.0001 9.50¡1.97 NS 27.97¡5.01 0.03 60.21¡29.91 ,0.0001
Deficient
Insufficient 5.14¡0.74 9.04¡2.23 25.91¡4.94 34.68¡13.94
Severely 5.69¡0.76 ,0.0001 9.50¡1.97 NS 27.97¡5.01 0.001 60.21¡29.91 ,0.0001
deficient
Sufficient 4.96¡0.61 8.46¡2.12 23.65¡4.45 29.38¡9.22
*Adjusted for maternal age, previous history of GDM, family history of type 2 DM and pre-pregnancy BMI.
25OHD: 25-hydroxyvitamin D, BMI: body mass index, DM: diabetes mellitus, GDM: gestational diabetes mellitus, iPTH: intact parathyroid hormone,
NS: non-significant, PGL: plasma glucose.
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Figure 2 - The inverse correlation between 25OHD and the A: fasting PGL, B: BMI and C: iPTH concentrations of the study participants. FPGL: fasting plasma
glucose (mmol/L), 25OHD: 25-hydroxyvitamin D (nmol/L), iPTH: intact parathyroid hormone (pg/ml), BMI: pre-pregnancy body mass index (kg/m2).
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a previous history of GDM, a history of type 2 DM in first-
degree relatives and pre-pregnancy BMI. In accordance with
previous results (5,15), we also found an inverse association
between 25OHD and fasting PGL.
Evidence suggests that both type 2 DM and GDM have
similar pathophysiologic features characterized by two
main metabolic defects: peripheral tissue resistance for
insulin and insufficient secretion of insulin by pancreatic b
cells to compensate for this peripheral tissue resistance
(16,17). Evidence also suggests a role for vitamin D in
maintaining normal glucose homeostasis (2). In both animal
and human studies, an association was shown between low
vitamin D levels and insulin resistance and impaired insulin
secretion (16). Moreover, specific receptors for 1-25 (OH)D3
have been demonstrated in pancreatic b cells, indicating the
possible role of vitamin D in the regulation of insulin
secretion (19). In a study by Maghbooli et al., maternal
serum 25OHD levels were inversely associated with home-
ostasis model assessment for insulin resistance (HOMA-IR),
demonstrating that 25OHD deficiency may contribute to
insulin resistance during pregnancy (4). However, the
results of studies evaluating the association between
25OHD and GDM are controversial (4-7). Maghbooli et al.
demonstrated that maternal serum levels of 25OHD during
24-28 weeks of pregnancy were significantly lower in
women with GDM compared with controls (4). Clifton-
Bligh et al. demonstrated an inverse association between
maternal serum 25OHD levels and fasting blood glucose,
although the association between 25OHD and GDMwas not
statistically significant (5). In a study performed in Indian
pregnant women, no significant association was found
between maternal serum levels of 25OHD and GDM risk
(6). In a recent study, Makgoba et al. did not find an
association between first trimester maternal serum 25OHD
levels and subsequent GDM development (7). However,
except for the study by Maghbooli et al., data regarding the
severity of 25OHD deficiency in subjects included in these
studies were insufficient. Therefore, the lack of an associa-
tion between low maternal serum 25OHD levels and GDM
in these studies may be due to the absence or very few
numbers of pregnant women with severely deficient
25OHD levels.
In addition to type 2 DM and insulin resistance, obesity is
a well-known risk factor for 25OHD deficiency (20-23). An
analysis of the NHANES 2003-2004 data also demonstrated
that 25OHD deficiency was highly prevalent in overweight
and obese subjects (24). Although a few studies have found
a relationship between pre-pregnancy BMI and low serum
levels of 25OHD during pregnancy (25), the results from this
study also suggest that a pre-pregnancy BMI.25 kg/m2 is
associated with severe 25OHD deficiency during the late
second and third trimesters of pregnancy. In accordance
with previous studies (26), this study also suggested that
pre-pregnancy BMI was significantly higher in women with
GDM compared with controls.
In the current study, iPTH levels were also significantly
higher in pregnant women with severely deficient 25OHD
levels compared to those with insufficient and sufficient
25OHD levels. Although no association was found between
iPTH and fasting or 2-hour PGLs, iPTH concentrations were
significantly higher in women with GDM compared to
controls. Increased PTH levels, either primary or secondary
to other disorders, have been shown to be associated with
impaired glucose tolerance (2,27,28), decreased insulin
sensitivity and an increased risk of diabetes in glucose-
tolerant subjects (9-11). Studies have suggested a two- to
fourfold increased risk of diabetes in subjects with hyper-
parathyroidism (9-11). Therefore, in addition to severe
25OHD deficiency, high PTH concentrations may have an
additional effect on glucose tolerance during pregnancy.
However, further studies are needed to explain the putative
role of high PTH concentrations on the pathogenesis of
GDM.
As demonstrated in the Hyperglycemia and Adverse
Pregnancy Outcome study (HAPO), even a mild increase in
fasting and 1-hour PGL corresponded to a significantly
higher odds ratio for neonatal birth weight and cord blood
c-peptide levels greater than the 90th percentile and
caesarean delivery (29). Therefore, if appropriate therapy
for severe 25OHD deficiency reduces the frequency or
severity of GDM, this could have prominent public health
significance.
An important limitation of our study was that maternal
serum 25OHD levels were assessed by a single measure-
ment during the late stage of pregnancy. Therefore, it may
not reflect the maternal 25OHD status during the entire
pregnancy. Another limitation was the cross-sectional
design of this study; as such, we could not determine the
neonatal outcomes of maternal 25OHD deficiency and also
could not suggest any causal relationship.
In conclusion, the results obtained from this study
provide novel data indicating that only severely deficient
maternal serum 25OHD levels during pregnancy are
significantly associated with an elevated relative risk of
GDM, even after adjusting for established risk factors of
GDM. As vitamin D deficiency is a worldwide public health
problem and its severe deficiency during pregnancy may
contribute to the development of GDM, the investigation of
25OHD deficiency during pregnancy and its appropriate
replacement, particularly in patients with severely deficient
levels, may contribute to the prevention of GDM. However,
although several studies have suggested an association
between 25OHD deficiency and DM, including GDM, more
evidence is required to determine the effect of vitamin D on
pancreatic b cells and peripheral insulin resistance.
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